Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 9/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.43 |
| ▸ | CDK2 | P24941 | 7/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | CCNE1 | P24864 | 5/20 | 0.40 |
| ▸ | CDK9 | P50750 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14043406 | 0.92 | GSK3B (0.56) | GSK3BCHEK1CDK2MAPK1HTT | |
| SCHEMBL13121497 | 0.92 | GSK3B (0.67) | GSK3BCDK2CCNE1 | |
| SCHEMBL13289498 | 0.91 | GSK3B (0.56) | GSK3BCHEK1CDK2CCNE1 | |
| SCHEMBL14043233 | 0.90 | GSK3B (0.56) | GSK3BCHEK1CDK2CCNE1CDK9 | |
| SCHEMBL13289156 | 0.89 | GSK3B (0.56) | GSK3BMEN1KMT2ACHEK1CDK2 | |
| SCHEMBL14613416 | 0.88 | GSK3B (0.52) | GSK3BCHEK1CDK2MAPK1HTT | |
| SCHEMBL13289145 | 0.87 | GSK3B (0.53) | GSK3BMEN1MAPTKMT2ACHEK1 | |
| SCHEMBL13305202 | 0.86 | GSK3B (0.52) | GSK3BMEN1KMT2ACHEK1CDK2 | |
| SCHEMBL13289230 | 0.86 | GSK3B (0.52) | GSK3BMAPTCHEK1MAPK1HTT | |
| SCHEMBL14418661 | 0.86 | GSK3B (0.54) | GSK3BCHEK1CDK2MAPK1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1720882-B1 | PYRAZOLOPYRIMIDINE-DERIVATIVES AS CYCLIN DEPENDENT KINASE INHIBITORS | SCHERING CORP (US) | 2011-01-05 | — | — | EP | disclosed |
| US-20070037824-A1 | Enzyme inhibitors from pyrazolo[1,5a]pyrimidine as enzyme inhibitors | SCHERING CORPORATION | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037824-A1 | Enzyme inhibitors from pyrazolo[1,5a]pyrimidine as enzyme inhibitors | CDK2, CDK5, CDKN1A | GSK3B 937/4885MEN1 3389/4885MAPT 2944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.